Organogenesis enters at-the-market equity sales agreement worth up to $75 million

On August 6, 2026, Organogenesis Holdings Inc. entered into an At-the-Market Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC, each acting as sales agents, allowing the company to offer and sell shares of its Class A common stock from time to time through the agents.¹

The shares are being sold under an existing registration. The Class A common stock is being offered under the company's previously filed shelf registration statement on Form S-3, filed August 8, 2024 and declared effective August 15, 2024.¹ Organogenesis filed a prospectus supplement dated August 6, 2026 for the offer and sale of the shares.¹ Under that supplement, the company may sell shares with an aggregate offering price of up to $75,000,000.¹

The sales structure gives Organogenesis flexibility rather than a fixed commitment. Sales may be made by any method that qualifies as an "at the market offering" under Rule 415(a)(4), including direct sales on the Nasdaq Capital Market, with the agents using commercially reasonable efforts based on instructions from the company, including price, time or size parameters.¹ The company is not obligated to sell any shares under the agreement.¹

Compensation terms were also disclosed. Organogenesis will pay the agents a commission of up to 3.0% of the gross sales price for each share sold under the agreement.¹ The company has also given the agents customary indemnification rights.¹

The offering will terminate when the Sales Agreement itself terminates according to its terms.¹ Foley Hoag LLP provided a legal opinion regarding the Class A common stock to be sold under the agreement, filed as an exhibit to the filing.¹